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infusion being least preferred (worst option in 45% of the cases). The second most 
relevant attribute was “necessity of combination therapy with methotrexate”, 
with DMARDs not requiring such combination being most preferred (in 43% of the 
cases). ConClusions: Our data indicate that, of the included attributes, the most 
important ones are route of administration (oral being the number one choice by 
majority) and combination therapy with methotrexate (with DMARDs not requiring 
such combination being the most preferred) for RA patients’ choice. This research 
was funded by Pfizer GmbH.
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objeCtives: Discrete-choice experiments are increasingly used to assess pref-
erences in health care. To date, very little is known about the transferability of 
patients’ preferences between jurisdictions. In this study, we aim to evaluate the 
preferences of patients with, or at risk of, osteoporosis for medication attributes 
in six European countries, and to assess whether preferences are transferable 
across these countries Methods: A discrete-choice experiment was conducted 
using a questionnaire in Belgium, France, Ireland, Spain, Switzerland and United 
Kingdom. Patients were asked to choose between two hypothetical unlabelled 
drug treatments (and an opt-out option) that vary in several attributes: efficacy 
in reducing the risk of fracture, type of potential common side-effects, mode 
and frequency of administration and out-of-pocket costs (only in countries with 
patients´ contribution on the cost of treatment). An efficient design was used to 
construct the treatment option choice sets and a mixed logit model was used to 
estimate patients’ preferences. Results: A total of 1,124 patients completed the 
experiment, with at least 100 patients per country. As expected, in all countries, 
patients preferred treatment with higher effectiveness and lower cost was pre-
ferred in the three countries in which a cost-attribute was part of the experiment. 
In all countries, patients preferred 6-monthly subcutaneous injection over weekly 
oral tablets. In most countries, patients also preferred monthly oral tablet and 
yearly intravenous injections over weekly oral tablets. Patients disliked being at 
risk of gastro-intestinal disorders more than being at risk of skin reactions and 
flu-like symptoms, except in Spain. There were significant differences between 
countries for some levels of attributes. ConClusions: This study suggests that 
the preferences of patients for osteoporotic drug therapy did not substantially 
differ between six European countries. However, for levels of some attributes, 
significant differences were observed.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA), 
including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), 
over 96 weeks (wks) of the RAPID-axSpA trial. Methods: The RAPID-axSpA trial 
(NCT01087762) is double-blind and placebo-controlled to Wk24, dose-blind to 
Wk48, and open-label to Wk204. Patients fulfilled ASAS criteria and had active 
axSpA. Patients originally randomized to CZP (200mg Q2W or 400mg Q4W, fol-
lowing 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in 
the dose-blind phase and OLE. Here we report PRO data for the CZP-treated rand-
omized set, including mean change from baseline and the proportion of patients 
achieving a Minimal Clinically Important Difference (MCID). Missing data were 
imputed by LOCF. Correlations between clinical and patient-reported outcomes 
were also investigated. Results: Of 218 patients randomized to CZP, 203 (93%) 
completed Wk24, 191 (88%) Wk48, and 174 (80%) Wk96. Rapid improvements from 
baseline to Wk24 were maintained to Wk96 in all patient subpopulations (overall 
axSpA, AS, nr-axSpA) in pain (Wk24: -3.2, -3.2, -3.3; Wk96: -3.6, -3.6, -3.7); fatigue 
(Wk24: -2.7, -2.5, -2.9; Wk96: -2.9, -2.8, -3.1); BASFI (Wk24: -2.4, -2.3, -2.4; Wk96: 
-2.6, -2.6, -2.6); ASQoL (Wk24: -5.1, -4.8, -5.5; Wk96: -5.7, -5.5, -6.1) and sleep (Wk24: 
-12.8, -10.5, -15.7; Wk96: -13.9, -11.6, -16.7). CZP-treated patients also maintained 
improvements in SF-36 components and domains. Sustained improvements in 
the proportion of patients (overall axSpA, AS, nr-axSpA) achieving MCID (%) were 
observed in fatigue (Wk24: 78.4, 76.0, 81.4; Wk96: 67.0, 70.2, 62.9); BASFI (Wk24: 
67.4, 68.6, 66.0; Wk96: 64.2, 68.6, 58.8) and ASQoL (Wk24: 69.3, 71.1, 67.0; Wk96: 65.6, 
66.9, 63.9). Similar outcomes were seen with both dosing regimens. Correlations 
were observed between improvements in PROs (pain/fatigue/SF-36) and clinical 
outcomes (ASDAS) (data not shown). ConClusions: Improvements in PROs 
(including pain, fatigue and ASQoL) were maintained over 96 wks in both the 
AS and nr-axSpA subpopulations. Sustained improvements in the proportion of 
patients achieving MCID were also reported.
95% CI: 0.53-2.07) and psoriasis (OR: 1.07; 95% CI: 0.56-2.03). ConClusions: More 
than half of the PsA patients were persistent with the index subcutaneous biologic 
over a 12-month period with similar persistence rates observed among those with 
and without psoriasis and DMARD use.
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objeCtives: To assess medication adherence to DMARD in patients with 
Rheumatoid Arthritis using CQR and MARS tools, identification of factors affecting 
adherence and its effect on quality of life. Methods: A randomly selected sample 
of 110 adult patients with RA on DMARDs admitted to hospital were asked about 
their medication adherence, through self-report questionnaire [CQR and MARS] and 
quality of life was assessed by HAQ (Health Assessment Questionnaire). Additionally, 
various factors affecting adherence were identified. Results: According to the tools 
used, 86.4% (CQR), 74.29% (MARS -mean cut point) and 95.45% (MARS -prior study 
cut point) of patients showed adherence towards DMARD. Better adherence was 
seen in patients with primary education (COR- 94%) or secondary education (MARS 
-83%). Patients who suffered from RA for more than 2yrs showed better adherence 
(CQR- 93%) compared to those with recent disease (< 2yrs) (CQR- 89%). Non adher-
ence was seen in patients having co-morbidities compared to patients with only RA 
(CQR- 91% vs 94%; MARS- 62% vs 82%). Mean HAQ of adherent patients was better 
(2.83±1.05) than non-adherent patients (3.23 ± 0.74). Adherent patients showed mod-
erately active disease state (Mean DAS – 5.96 ± 1.67) whereas, non-adherent patients 
showed highly active disease state (Mean DAS – 6.70 ± 0.84). ConClusions: Patient 
reported questionnaires showed disease duration of less of 2yrs, and patients with 
co-morbidities lead to Non-adherence which worsened disease activity which lead 
to decreased quality of life.
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objeCtives: Psoriatic arthritis (PsA) is a multi-factorial disease that affects the skin, 
joints and soft tissues. Two of the commonly used measures for PsA are the Psoriasis 
Area and Severity Index (PASI, 0-100 scale) and the Health Assessment Questionnaire 
(HAQ, 0-3 scale) for skin and joints symptoms, respectively. Previous work in the 
area has estimated a relationship between these patient-reported instruments and 
utility (SF-36 mapped to the EQ-5D). The objectives of this study were to calculate 
patient-reported utility and investigate the consistency of the relationship between 
PASI, HAQ and utility with previously published estimates, based on the PSUMMIT 
trials of ustekinumab versus placebo. Methods: Patient level data from PSUMMIT1 
(anti-TNFα naïve) and PSUMMIT2 (both anti-TNFα naïve and experienced) were 
analysed in Stata 11. SF-36 data were converted to EQ-5D using the mapping by 
Rowen et al., with regression analysis used to estimate the relationship between 
PASI, HAQ and the resulting utility (including multiplicative terms). Goodness of fit 
was determined by the adjusted R2 and Root Mean Squared Error (RMSE). Results: 
Anti-TNFα naïve and experienced patients had a baseline utility of 0.50 and 0.48, 
respectively. Utility improved over the 24-week blinded period by 0.04/0.06 in the 
placebo arms for anti-TNFα naïve and experienced, and 0.11/0.13 in the treatment 
arms. In regression analysis utility was predicted as 0.897 – 0.004xPASI - 0.298xHAQ 
(adjusted R2 0.60, RMSE 0.12), similar to previously published estimates. Adding a 
multiplicative term for PASI and HAQ did not improve goodness of fit statistics, 
although baseline methotrexate use was linked to a lower utility. ConClusions: 
Patients with PsA have a low level of health-related quality of life that improves with 
treatment. The determinants of utility in the PSUMMIT trials were the skin and joint 
symptoms faced by patients, in keeping with previous estimates.
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objeCtives: There is a variety of biologic and non-biologic disease modifying anti-
rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). 
These DMARDs are associated with different characteristics in key attributes such as 
mode of administration, side effects, etc. The current study assessed the importance 
of treatment characteristics for RA patients’ preferences. Methods: In a discrete 
choice experiment (DCE), 1570 RA patients are asked to choose the most and the 
least preferred DMARD (best-worst-scaling) among hypothetical multi-attribute 
treatment alternatives with varying levels of key attributes, as defined in focus 
groups: mode of administration, frequency of administration, time till onset of 
drug effect, necessity of combination therapy with methotrexate, and side effects. 
The multi-profile case design simulates a real choice situation between different 
hypothetical treatment alternatives. Interim analysis was conducted after half the 
sample size had been reached. Results: Interim analysis included 836 patients 
from 33 office based rheumatologists across Germany. Majority of patients were 
female (74%), 50 to 64 years of age (46%), with < 10 years of disease duration (54%), 
and reported experience with injectable DMARDs (63%). Mode of administration 
appeared the most important attribute guiding patients’ preferences, with ‘oral 
application’ being most desired (selected as best option in 51% of the cases) and 
